person · Reporting owner
Whelan, Jr. Robert M.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Director | July 01, 2020 | July 06, 2020 |
| iANTHUS CAPITAL HOLDINGS, INC.ITHUF · Entity 7387 | Director | February 05, 2021 | February 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.39 · Expires 2030-07-01 | Direct | 20,000 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Grant · Acquired 20,000 · Balance 20,000 |
iANTHUS CAPITAL HOLDINGS, INC.
Report date February 05, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2021-02-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 50,000 |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2029-12-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The exercise price is denominated and reported in Canadian Dollars. F1: On December 5, 2019, the Issuer granted the Reporting Person options to purchase up to 116,860 common shares. The options vest as follows: 19,477 options vested on June 30, 2020 and the balance of the options vest in 10 equal quarterly installments with the first installment vesting on September 30, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 5, 2019, the Issuer granted the Reporting Person options to purchase up to 116,860 common shares. The options vest as follows: 19,477 options vested on June 30, 2020 and the balance of the options vest in 10 equal quarterly installments with the first installment vesting on September 30, 2020.
F2: The exercise price is denominated and reported in Canadian Dollars.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ASPENTECH Corp
Report date May 16, 2022 · Filed May 18, 2022
Section 16 reporting ended · disclosed 2022-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 1
1 source rowRow 1 · 2022-05-16 · Disposition to issuer · Disposed 13,691 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.54 · Expires 2023-07-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-16 · Disposition to issuer · Disposed 3,496 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F3: The option granted at the exercise price of $32.54 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.44 · Expires 2024-07-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-16 · Disposition to issuer · Disposed 2,619 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F6: The option granted at the exercise price of $43.44 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.38 · Expires 2025-08-02 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-16 · Disposition to issuer · Disposed 3,307 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F7: The option granted at the exercise price of $44.38 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.46 · Expires 2026-08-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-16 · Disposition to issuer · Disposed 3,666 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F8: The option granted at the exercise price of $45.46 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.25 · Expires 2027-08-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-16 · Disposition to issuer · Disposed 2,823 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F9: The option granted at the exercise price of $63.25 was fully vested on the date of grant. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.36 · Expires 2028-09-03 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-16 · Disposition to issuer · Disposed 1,605 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F10: The option granted at the exercise price of $115.36 was fully vested on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech.
F3: The option granted at the exercise price of $32.54 was fully vested on the date of grant.
F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time.
F5: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent.
F6: The option granted at the exercise price of $43.44 was fully vested on the date of grant.
F7: The option granted at the exercise price of $44.38 was fully vested on the date of grant.
F8: The option granted at the exercise price of $45.46 was fully vested on the date of grant.
F9: The option granted at the exercise price of $63.25 was fully vested on the date of grant.
F10: The option granted at the exercise price of $115.36 was fully vested on the date of grant.
Aspen Technology, Inc.
Report date March 11, 2025 · Filed March 13, 2025
Section 16 reporting ended · disclosed 2025-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-03-11 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-03-11 · Other · Disposed 7,344 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 26, 2025, among Aspen Technology, Inc. (the "Issuer"), Emerson Electric Co. ("Parent"), and Emersub CXV, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") not already owned by Parent and thereafter merged with and into the Issuer, effective as of March 12, 2025 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $265.00 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-03-12 · Disposition to issuer · Disposed 1,196 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a "Company RSU"). F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU held by a non-employee director of the Issuer (whether vested or unvested) was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to the product of (1) the Merger Consideration and (2) the number of Shares subject to such Company RSU. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.03 · Expires 2026-08-31 | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-12 · Disposition to issuer · Disposed 3,266 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.81 · Expires 2025-08-02 | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-12 · Disposition to issuer · Disposed 2,946 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.99 · Expires 2027-08-31 | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-12 · Disposition to issuer · Disposed 2,515 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $129.48 · Expires 2028-09-03 | Direct | 0 |
Reported balance
After 2025-03-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-12 · Disposition to issuer · Disposed 1,430 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 26, 2025, among Aspen Technology, Inc. (the "Issuer"), Emerson Electric Co. ("Parent"), and Emersub CXV, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") not already owned by Parent and thereafter merged with and into the Issuer, effective as of March 12, 2025 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $265.00 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a "Company RSU").
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU held by a non-employee director of the Issuer (whether vested or unvested) was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to the product of (1) the Merger Consideration and (2) the number of Shares subject to such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2020 Filed Jul 6, 2020 16:31 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-20-081239 · a4.xml · derivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-01 Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 06:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionConvertible Note · Derivative | 11,176 | $4.80 | $53,644.80 |
DisclosureSEC source: 0001104659-20-010942 · a4.xml · derivative · entry 5 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · shares: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · derivative.exercise_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F3 · derivative.expiration_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 06:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A-1 Preferred Stock · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010942 · a4.xml · derivative · entry 4 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 06:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 11,176 | $4.80 | $53,644.80 |
DisclosureSEC source: 0001104659-20-010942 · a4.xml · nonDerivative · entry 3 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 06:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 59,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-010942 · a4.xml · nonDerivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 06:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 25,000 | $6.00 | $150,000.00 |
DisclosureSEC source: 0001104659-20-010942 · a4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:43 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,444 | $133.20 Strike: $133.20 | $192,340.80 |
DisclosureSEC source: 0001127602-19-027999 · form4.xml · derivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444 Underlying: Common Stock · 1,444 shares Expires 2029-09-02 F3 · derivative.exercise_date: The option granted at the exercise price of $133.20 was fully vested on the date of grant. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:43 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 732 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-027999 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,964 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock Units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:17 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 1,250 | $96.86 | $121,075.00 |
DisclosureSEC source: 0001127602-19-004058 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,232 Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:25 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,605 | $115.36 Strike: $115.36 | $185,152.80 |
DisclosureSEC source: 0001127602-18-026967 · form4.xml · derivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605 Underlying: Common Stock · 1,605 shares Expires 2028-09-03 F3 · derivative.exercise_date: The option granted at the exercise price of $115.36 was fully vested on the date of grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:25 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-026967 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,482 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. The Restricted Stock Units were fully vested on the date of grant. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 16:56 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 1,250 | $107.76 | $134,705.00 |
DisclosureSEC source: 0001127602-18-026013 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637 Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:14 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 1,500 | $88.03 | $132,045.00 |
DisclosureSEC source: 0001127602-18-015954 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,887 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:48 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 1,772 | $72.30 | $128,106.74 |
DisclosureSEC source: 0001127602-18-006195 · form4.xml · nonDerivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,387 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:48 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 400 | $72.21 | $28,884.40 |
DisclosureSEC source: 0001127602-18-006195 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,159 Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 17:55 UTC | ASPENTECH Corp AZPN · Entity 127212 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-17-031527 · form4.xml · derivative · entry 3 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option granted at the exercise price of $14.38, representing a right to purchase 24,000 shares, became exercisable in 12 equal consecutive quarterly installments on the last business day of each quarter, beginning on September 30, 2011. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 17:55 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 10,000 | $66.01 | $660,100.00 |
DisclosureSEC source: 0001127602-17-031527 · form4.xml · nonDerivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.88 to $66.13, inclusive. The reporting person undertakes to provide to Aspen Technology, Inc., any security holder of Aspen Technology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 17:55 UTC | ASPENTECH Corp AZPN · Entity 127212 | Exercise / conversionCommon Stock | 14,000 | $14.38 | $201,320.00 |
DisclosureSEC source: 0001127602-17-031527 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 17:31 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,823 | $63.25 Strike: $63.25 | $178,554.75 |
DisclosureSEC source: 0001127602-17-027081 · form4.xml · derivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 2,823 shares Expires 2027-08-31 F3 · derivative.exercise_date: The option granted at the exercise price of $63.25 was fully vested on the date of grant. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 17:31 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 1,542 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-027081 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,559 F1 · security: Each Restricted Stock Unit represents a right to receive one share of Aspen Technology, Inc. common stock. F2 · price: Restricted Stock Units do not have an exercise price. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 16:50 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 700 | $54.21 | $37,947.70 |
DisclosureSEC source: 0001127602-17-004794 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,017 Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 16:26 UTC | ASPENTECH Corp AZPN · Entity 127212 | SaleCommon Stock | 2,000 | $48.34 | $96,680.00 |
DisclosureSEC source: 0001127602-16-066242 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,717 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.31 to $48.36, inclusive. The reporting person undertakes to provide to Aspen Technology, Inc., any security holder of Aspen Technology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 16:54 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,666 | $45.46 Strike: $45.46 | $166,656.36 |
DisclosureSEC source: 0001127602-16-061951 · form4.xml · derivative · entry 2 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,666 Underlying: Common Stock · 3,666 shares Expires 2026-08-31 F3 · derivative.exercise_date: The option granted at the exercise price of $45.46 was fully vested on the date of grant. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 16:54 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 2,145 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-061951 · form4.xml · nonDerivative · entry 1 Whelan, Jr. Robert M. · CIK 0001490045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,717 F1 · security: Each Restricted Stock Unit represents a right to receive one share of Aspen Technology, Inc. common stock. F2 · price: Restricted Stock Units do not have an exercise price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.